By integrating multiple datasets analyses and functional validation, we have delineated a novel PHOX1-NGFR-ERK1/2 signaling cascade that drives GC aggressiveness and correlates with adverse clinical outcomes. This evidence concerns the gene PRRX1 and gastric cancer.